Neurodegenerative Genes Polymorphisms of the -491A/T APOE, the -877T/C APP and the Risk of Primary Open-angle Glaucoma in the Polish Population

References

• Mozaffarieh M, Grieshaber MC, Flammer J. Oxygen and blood flow: players in the pathogenesis of glaucoma. Mol Vis 2008;14:224–233
   PubMed Web of Science ®Google Scholar
• Karna-Matyjaszek U, Sierżantowicz R, Mariak Z. Acceptance of own disease by patients with diagnosed glaucoma. Pol Merk Lek 2010;163:37–41
   Google Scholar
• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262–267
   PubMed Web of Science ®Google Scholar
• Fuse N. Genetic bases for glaucoma. Tohoku J Exp Med 2010;221:1–10
   PubMed Web of Science ®Google Scholar
• Butterfield DA, Lauderback M. Lipid peroxidation and protein oxidation in Alzheimer’s disease brain: potential causes and consequences involving amyloid beta-peptide associated free radical oxidative stress. Free Radic Biol Med. 2002;32:1050–1060
   PubMed Web of Science ®Google Scholar
• Lv H, Jia L, Jia J. Promoter polymorphisms which modulate APP expression may increase susceptibility to Alzheimer’s disease. Neurobiol Aging 2008;29:194–202
   PubMedGoogle Scholar
• Morin PJ, Abraham CR, Amaratunga A, et al. Amyloid precursor protein is synthesized by retinal ganglion cells, rapidly transported to the optic nerve plasma membrane and nerve terminals, and metabolized. J Neurochem 1993;61:464–473
   PubMedGoogle Scholar
• McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, et al. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci 2002;43:1077–1087
   PubMed Web of Science ®Google Scholar
• McKinnon SJ. Glaucoma: ocular Alzheimer’s disease? Front Biosci 2003;8:1140–1156
   Web of Science ®Google Scholar
• Eto M, Watanabe K, Ishii K. A racial difference in apolipoprotein E allele frequencies between the Japanese and Caucasian populations. Clin Genet 1986;30:422–427
   PubMed Web of Science ®Google Scholar
• Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988;240:622–630
   PubMed Web of Science ®Google Scholar
• Benjamin R, Leake A, Edwardson JA, et al. Apolipoprotein E genes in Lewy body and Parkinson’s disease. Lancet 1994;343:1565
   PubMedGoogle Scholar
• Drory VE, Birnbaum M, Korczyn AD, Chapman J. Association of APOE epsilon4 allele with survival in amyotrophic lateral sclerosis. J Neurol Sci 2001;190:17–20
   PubMed Web of Science ®Google Scholar
• Mann DM, Iwatsubo T, Pickering-Brown SM, et al. Preferential deposition of amyloid beta protein (Abeta) in the form Abeta40 in Alzheimer’s disease is associated with a gene dosage effect of the apolipoprotein E E4 allele. Neurosci Lett 1997;221:81–84
   PubMed Web of Science ®Google Scholar
• Bullido MJ, Valdivieso F. Apolipoprotein E gene promoter polymorphisms in Alzheimer’s disease. Microsc Res Techniq 2000;50:261–267
   PubMedGoogle Scholar
• Lambert JC, Pasquier F, Cottel D, et al. A new polymorphism in the Apoe promoter associated with risk of developing Alzheimer’s disease. Hum Mol Genet 1998;7:533–540
   PubMedGoogle Scholar
• Artiga MJ, Bullido MJ, Frank A, et al. Risk for Alzheimer’s disease correlates with transcriptional activity of the APOE gene. Hum Mol Genet 1998;7:1887–1892
   PubMedGoogle Scholar
• Bullido MJ, Artiga MJ, Recuero M, et al. A polymorphism in the regulatory region of APOE associated with risk for Alzheimer’s dementia. Nat Genet 1998;18:69–71
   PubMed Web of Science ®Google Scholar
• Wang JC, Kwon JM, Shah P, et al. Effect of APOE genotype and promoter polymorphism on risk of Alzheimer’s disease. Neurology 2000;55:1644–1649
   PubMed Web of Science ®Google Scholar
• Zurutuza L, Verpillat P, Raux G, et al. APOE promoter polymorphisms do not confer independent risk for Alzheimer’s disease in a French population. Eur J Hum Genet 2000;8:713–716
   PubMed Web of Science ®Google Scholar
• Amaratunga A, Abraham CR, Edwards RB, et al. Apolipoprotein E is synthesized in the retina by Müller glial cells, secreted into the vitreous, and rapidly transported into the optic nerve by retinal ganglion cells. J Biol Chem 1996;271:5628–5632
   PubMed Web of Science ®Google Scholar
• Artiga MJ, Bullido MJ, Sastre I, et al. Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS Lett 1998;421:105–108
   PubMedGoogle Scholar
• Copin B, Brézin AP, Valtot F, et al. Apolipoprotein E-promoter single-nucleotide polymorphisms affect the phenotype of primary open-angle glaucoma and demonstrate interaction with the myocilin gene. Am J Hum Genet 2002; 70:1575–1581
   PubMed Web of Science ®Google Scholar
• Ressiniotis T, Griffiths PG, Birch M, et al. Apolipoprotein E promoter polymorphisms do not have a major influence on the risk of developing primary open angle glaucoma. Mol Vis 2004;10:805–807
   PubMedGoogle Scholar
• Lam CY, Fan BJ, Wang DY, et al. Association of apolipoprotein E polymorphisms with normal tension glaucoma in a Chinese population. J Glaucoma 2006;15:218–222
   PubMedGoogle Scholar
• Fan BJ, Wang DY, Fan DS, et al. SNPs and interaction analyses of myocilin, optineurin, and apolipoprotein E in primary open angle glaucoma patients. Mol Vis 2005;11:625–631
   PubMed Web of Science ®Google Scholar
• Vickers JC, Craig JE, Stankovich J, et al. The apolipoprotein epsilon4 gene is associated with elevated risk of normal tension glaucoma. Mol Vis 2002;8:389–393
   PubMed Web of Science ®Google Scholar
• Ressiniotis T, Griffiths PG, Birch M, et al. The role of apolipoprotein E gene polymorphisms in primary open-angle glaucoma. Arch Ophthalmol 2004;122:258–261
   PubMedGoogle Scholar
• Harwerth RS, Vilupuru AS, Rangaswamy NV, Smith EL. The relationship between nerve fiber layer and perimetry measurements. Invest Ophthalmol Vis Sci 2007;48:763–773
   PubMed Web of Science ®Google Scholar
• Sommer A, Katz J, Quigley HA, et al. Clinically detectable nerve fiber atrophy precedes the onset of glaucomatous field loss. Arch Ophthalmol 1991;109:77–83
   PubMed Web of Science ®Google Scholar
• Bayera AU, Ferrarib F, Erbb C. High occurrence rate of glaucoma among patients with Alzheimer’s disease. Eur Neurol 2002;47:165–168
   PubMedGoogle Scholar
• Sadun AA, Bassi CJ. Optic nerve damage in Alzheimer’s disease. Ophthalmology 1990;97:9–17
   PubMed Web of Science ®Google Scholar
• Laws SM, Taddei K, Martins G, et al. The -491AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer’s disease. Neuroreport 1999;10:879–882
   PubMedGoogle Scholar
• Laws SM, Hone E, Taddei K, et al. Variation at the APOE -491 promoter locus is associated with altered brain levels of apolipoprotein E. Mol Psychiatry 2002;7:886–890
   PubMedGoogle Scholar
• Lambert JC, Mann D, Goumidi L, et al. Effect of the APOE promoter polymorphisms on cerebral amyloid peptide deposition in Alzheimer’s disease. Lancet 2001;357:608–609
   PubMed Web of Science ®Google Scholar
• Hanson AJ, Prasad JE, Nahreini P, et al. Overexpression of amyloid precursor protein is associated with degeneration, decreased viability, and increased damage caused by neurotoxins (prostaglandins A1 and E2, hydrogen peroxide, and nitric oxide) in differentiated neuroblastoma cells. J Neurosci Res 2003;74:148–159
   PubMedGoogle Scholar
• Chen XH, Siman R, Iwata A, et al. Long-term accumulation of amyloid-beta, beta-secretase, presenilin-1, and caspase-3 in damaged axons following brain trauma. Am J Pathol 2004;165:357–371
   PubMed Web of Science ®Google Scholar
• Ikonomovic MD, Uryu K, Abrahamson EE, et al. Alzheimer’s pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol 2004;190:192–20
   PubMed Web of Science ®Google Scholar